Crosslinked Fibrin Fragment (X‐ FIB ) as a Biomarker for Endotype Differentiation and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria

Documenti analoghi

• Temporal Trends in the Course and Management of Chronic Urticaria at a European Tertiary Center
  di: Clara Emilie Syrene Østergaard, et al.
  Pubblicazione: (2025)
• Plasma proteomics analysis of patients with chronic spontaneous urticaria reveals significant associations with key disease characteristics but not with response to omalizumab treatment
  di: Misbah Noshela Ghazanfar, et al.
  Pubblicazione: (2024)
• Efficacy of Omalizumab, Dupilumab, and Remibrutinib in Chronic Spontaneous Urticaria: Phase Data and Placebo Response
  di: Murat Türk, et al.
  Pubblicazione: (2025)
• Perceived Acquired Resistance to Omalizumab in Obese Patients With Chronic Spontaneous Urticaria
  di: Francisco Martins, et al.
  Pubblicazione: (2026)
• Towards Personalised Therapy in Chronic Spontaneous Urticaria: Advancing From Endotype to Clinical Response
  di: Katie Ridge, et al.
  Pubblicazione: (2025)